(IN BRIEF) AstraZeneca and Alexion have reported positive interim Phase III results for Ultomiris in treating immunoglobulin A nephropathy, showing a significant reduction in proteinuria compared to placebo. The therapy demonstrated rapid effects as early as week 10 and met … Read the full press release →
Posted in Business, Healthcare, Investment, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, AstraZeneca, AstraZeneca Advances Kidney Disease Pipeline with Promising Results for Ultomiris in Global Study, biologics, Chronic kidney disease, clinical research, complement system, end-stage kidney disease, I CAN study, IgAN, immunoglobulin A nephropathy, Jonathan Barratt, kidney disease, Marc Dunoyer, nephrology, New Phase III Data Support Potential of Ultomiris as Disease-Modifying Therapy in IgA Nephropathy, Phase III Trial, proteinuria, rare diseases, ravulizumab, renal medicine, treatment development, Ultomiris
(IN BRIEF) Voydeya (danicopan), a first-in-class oral Factor D inhibitor, has been recommended for marketing authorization in the European Union (EU) as an add-on to ravulizumab or eculizumab for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who experience residual haemolytic … Read the full press release →
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, eculizumab, Marc Dunoyer, PNH, Professor Hubert Schrezenmeier, ravulizumab, safety, treatment, Voydeya
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
